期刊文献+
共找到320篇文章
< 1 2 16 >
每页显示 20 50 100
ALTERNATING CHEMOTHERAPY AND FRACTIONATED RADIOTHERAPY AS A MODALITY FOR THE TREATMENT OF PRIMARY LIVER CANCER 被引量:1
1
作者 陆继珍 李炳鑫 +2 位作者 刘康达 余业勤 汤钊猷 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 1994年第1期69-73,共5页
Alternating chemotherapy and fractionated radiotherapy were carried out in 32 patients with surgically proven unresectable primary liver cancer (PLC).After initial surgical intervention of hepatic artery ligation and ... Alternating chemotherapy and fractionated radiotherapy were carried out in 32 patients with surgically proven unresectable primary liver cancer (PLC).After initial surgical intervention of hepatic artery ligation and cannulation,the tumor war localized with silver clips.The cisplatin 20 mg was infused via a hepatic artery catheter per day on the first 3 consecutive days.Fractionated radiation(18MV straight linear accelerator)of 250 cGy,twice a day with an interval of 6 hours,was then followed on the 8th,9th and 10th days.The cycle was repeated 3 or 4 times.The shrinkage of tumors and decrease of AFP level were observed in 100%(32/32)and 5% (19/21)of the patients respectively.A second-stage resection was done in 37.5%(12/32)of the patients.The 1-,3- and 5-year survival rates after resection were 96.7% ,67.5% and 67. 5 % respectively.It is suggested that this modality is a choice of therapies which can convert some unresectable large PLC to resectable ones. 展开更多
关键词 fractionated radiotherapy CHEMOTHERAPY CISPLATIN Primary liver cancer Second-stage resection.
下载PDF
Hypofractionated versus Conventionally Fractionated Radiotherapy in Post-Mastectomy Breast Cancer Patients
2
作者 Fatma M. F. Akl Ashraf Khater 《Journal of Cancer Therapy》 2018年第11期941-954,共14页
Background & Objective: Hypofractionation has been used in curative setting in breast conservative surgery, but still no adequate information about its application in the adjuvant setting after mastectomy in breas... Background & Objective: Hypofractionation has been used in curative setting in breast conservative surgery, but still no adequate information about its application in the adjuvant setting after mastectomy in breast cancer patients. The aim of this trial was to assess the efficacy and toxicity of hypofractionation radiotherapy (40 Gy in 15 fractions) in post mastectomy breast cancer patients and to compare these results with those of post mastectomy patients treated retrospectively by conventional radiotherapy (50 Gy in 25 fractions) as regard overall survival (OS), disease free survival (DFS), locoregional disease free survival (LDFS), and toxicities. Patients & Methods: One hundred post mastectomy breast cancer patients were included into this study, they were divided into 2 groups, the 1st included 50 patients treated prospectively with hypofractionated radiotherapy regimen (40 Gy in 15 fractions), and the 2nd (control group) included 50 patients treated retrospectively with conventionally fractionated radiotherapy regimen (50 Gy in 25 fractions). Results: The 2 year overall survival were 96% & 94% respectively (p = 0.7), while the disease free survival were 91% & 89.8%, respectively (p = 0.9), and the LDFS were 95.8% & 93.3%, respectively (p = 0.9), G1 acute dermatitis was observed in 22 (44%) & 25 (50%) patients in group I & II respectively, G2 in 8 (16%) & 10 (20%) patients respectively, no G4 skin toxicity was detected. Radiation pneumonitis was observed in 2 patients (4%) only in group II. Conclusion: post-mastectomy hypofractionated radiation therapy achieved comparable survival and toxicity to the conventionally fractionated radiotherapy with the advantage of reducing overall treatment time, treatment burden & cost. 展开更多
关键词 Breast Cancer ADJUVANT radiotherapy HYPOfractionATION Conventional fractionATION
下载PDF
小剂量分次放疗增敏化疗在转移性结直肠癌治疗中的临床研究
3
作者 熊春 黄丹 马智 《川北医学院学报》 CAS 2024年第2期194-197,共4页
目的:探究小剂量分次放疗增敏化疗在转移性结直肠癌(mCRC)治疗中的疗效及安全性。方法:根据治疗方式不同将72例一线化疗失败的mCRC患者分为观察组(n=37)和对照组(n=35)。对照组采用贝伐珠单抗^(+)化疗二线治疗。随访两年,比较两组患者... 目的:探究小剂量分次放疗增敏化疗在转移性结直肠癌(mCRC)治疗中的疗效及安全性。方法:根据治疗方式不同将72例一线化疗失败的mCRC患者分为观察组(n=37)和对照组(n=35)。对照组采用贝伐珠单抗^(+)化疗二线治疗。随访两年,比较两组患者的临床疗效、不良反应发生情况(白细胞、血小板)、治疗前后的血清肿瘤标志物水平[癌胚抗原(CEA)、糖类抗原199(CA199)]、免疫功能(CD3^(+)、CD4^(+)、CD8^(+))和生存情况[总生存期(OS)、无进展生存期(PFS)]。结果:观察组治疗后总有效率高于对照组(20.00%vs.43.24%,P<0.05);治疗后,两组CEA、CA199水平低于治疗前,且观察组低于对照组(P<0.05);两组CD3^(+)、CD4^(+)水平上升,且观察组高于对照组(P<0.05);CD8^(+)下降,且观察组低于对照组(P<0.05);两组白细胞下降、血小板减少等不良反应发生情况比较,差异无统计学意义(P>0.05);观察组两年OS、PFS分别为62.16%、40.54%,均高于对照组的37.14%、17.14%(P<0.05)。结论:小剂量分次放疗增敏化疗联合贝伐珠单抗^(+)化疗二线治疗mCRC具有较好的临床疗效,能改善患者的血清肿瘤标志物水平,提高其免疫功能,延长患者生存期,且具有一定安全性。 展开更多
关键词 转移性结直肠癌 小剂量分次放疗 增敏化疗 贝伐珠单抗 化疗
下载PDF
大体积脑转移瘤大分割后程缩野放疗的剂量学及临床疗效分析
4
作者 张凯燕 谢琛 +1 位作者 张怀文 李俊玉 《实用癌症杂志》 2024年第4期620-623,共4页
目的探讨大分割后程缩野放疗对大体积脑转移瘤患者的剂量学及其临床疗效分析。方法收集20例病灶体积6~20 cm^(3)、病灶数目1~4个且行大分割后程缩野放疗的脑转移瘤患者资料。脑部病灶处方剂量为52.5 Gy/3.5 Gy/15 f。治疗10次后复查颅... 目的探讨大分割后程缩野放疗对大体积脑转移瘤患者的剂量学及其临床疗效分析。方法收集20例病灶体积6~20 cm^(3)、病灶数目1~4个且行大分割后程缩野放疗的脑转移瘤患者资料。脑部病灶处方剂量为52.5 Gy/3.5 Gy/15 f。治疗10次后复查颅脑增强MRI评估疗效、若肿瘤退缩明显重新勾画靶区完成后程放疗。评估不缩野放疗计划(Plan1)和后程缩野放疗计划下(Plan2)脑组织及其他危及器官剂量学参数变化、后程计划缩瘤率、近期疗效(疗后2~3个月评估近期疗效)。结果后程缩野放疗中脑组织及危及器官的辐射剂量都有下降。且后程缩野时平均缩瘤率为41.76%,3个月ORR为90.5%,6个月LCR为100%。结论大分割后程缩野放疗缩瘤率高,能有效减少正常组织剂量学参数值,对大体积病灶局部控制率好,近期疗效佳。 展开更多
关键词 大体积脑转移瘤 大分割放疗 后程缩野放疗
下载PDF
基于LQ模型的原发性肝癌立体定向放射治疗剂量学实验
5
作者 万福莺 周凌宏 《中国医学物理学杂志》 CSCD 2024年第6期673-677,共5页
目的:探讨肝癌立体定向放射治疗(SBRT)的剂量学效应是否符合线性二次(LQ)模型。方法:选取体外培养的人肝癌细胞株HepG2和Hep3B,给予生物有效剂量(BED)照射(6、8、10、12、14 Gy)。照射分割方式包括单次照射(模拟SBRT)和分次照射3次、5次... 目的:探讨肝癌立体定向放射治疗(SBRT)的剂量学效应是否符合线性二次(LQ)模型。方法:选取体外培养的人肝癌细胞株HepG2和Hep3B,给予生物有效剂量(BED)照射(6、8、10、12、14 Gy)。照射分割方式包括单次照射(模拟SBRT)和分次照射3次、5次(模拟IMRT)。检测辐照后存活分数反应不同分割方式的损伤效应;绘制生存曲线,观察不同分割方式对细胞增殖的影响;辐照后细胞划痕实验,观察不同分割方式对细胞侵袭和迁移能力的影响。结果:LQ模型在肝癌SBRT放疗的应用体外验证中出现明显的分离效应。对于HepG2细胞和Hep3B细胞,当BED<12 Gy(α/β=10 Gy)时,不同分割方式在损伤效应、增殖能力、侵袭能力上未显示出明显差异,SBRT符合LQ模型;当BED≥12 Gy时,单次分割相对于多次分割,显示出更高的损伤效应,即SBRT损伤效应高于IMRT。结论:SBRT在肝癌中适用LQ模型具有一定的剂量区间,超过该区间损伤效应高于LQ模型预测结果。 展开更多
关键词 肝癌 线性二次模型 剂量分割 立体定向放射治疗
下载PDF
Therapeutic Effects of Stereotactic Radiotherapy on 389 Cases of Brain Glioma 被引量:1
6
作者 牛道立 何中 胡慧玲 《The Chinese-German Journal of Clinical Oncology》 CAS 2005年第4期221-224,共4页
Objective: To investigate the treatment effectiveness and side effects of stereotactic radiotherapy for brain glioma. Methods: From Jun. 1995 to Dec. 1998, 389 cases of brain gliomas were treated by stereotactic rad... Objective: To investigate the treatment effectiveness and side effects of stereotactic radiotherapy for brain glioma. Methods: From Jun. 1995 to Dec. 1998, 389 cases of brain gliomas were treated by stereotactic radiotherapy, among which 151 cases were treated by stereotactic radiosurgery (SRS) and the other 238 cases, by fractionated stereotactic radiotherapy (FSRT). In the SRS group, the marginal tumor dose was 20 to 30 Gy (median, 2.6 Gy). One to 6 isocenters (median, 2.48) and 5 to 21 irradiation arcs (median, 8.45) were applied. In the FSRT group, the per-fraction marginal tumor dose was 8 to 12 Gy with 1 to 6 isocenters (median, 2.53), 6 to 20 irradiation arcs (median, 8.25) and 2-5 fractions delivered everyday or every other day. Results: Three months after treatment, the complete and partial response rates were 13.9% and 45.7% in SRS group respectively. The stable disease rate was 17.2%. The total effective rate was 76.8%. In FSRT group, the complete and partial remission rates were 19.7% and 47.9% respectively. The stable disease rate was 20.6%. The total effective rate was 88.2%. The total effective rate of FSRT group was higher than that in SRS group (X^2=9.874, P=0.020). The 1-year, 3-year and 5-year survival rate of all patients was 54.3%, 29.3%, 16.5% respectively. The 1-year, 3-year and 5-year survival rate in SRS group and FSRT group was 52.3% vs 26.5%, 11.9% vs 55.5%, and 31.1 vs 19.3% respectively. There was no significant difference between the two groups (X^2=2.16, P=0.1417). The brain edema caused by the main radiation was more severe in the SRS group than in FSRT group (X^2=4.916, P=0.027). Conclusion: It is effective for brain glioma to be treated by stereotactic radiotherapy. Compared with SRS, the FSRT has the advantage of good effect and less side response. 展开更多
关键词 fractionated stereotactic radiotherapy stereotactic radiosurgery brain glioma PROGNOSIS
下载PDF
分次立体定向放疗联合全脑放疗治疗乳腺癌脑转移患者的临床疗效
7
作者 陈晓亮 王豪杰 王红旗 《癌症进展》 2024年第8期881-884,共4页
目的探讨分次立体定向放疗(FSRT)联合全脑放疗治疗乳腺癌脑转移患者的临床疗效。方法采用随机数字表法将140例乳腺癌脑转移患者分为观察组和对照组,每组70例,对照组患者采取全脑放疗,观察组患者采取FSRT联合全脑放疗。比较两组患者的近... 目的探讨分次立体定向放疗(FSRT)联合全脑放疗治疗乳腺癌脑转移患者的临床疗效。方法采用随机数字表法将140例乳腺癌脑转移患者分为观察组和对照组,每组70例,对照组患者采取全脑放疗,观察组患者采取FSRT联合全脑放疗。比较两组患者的近期疗效、生活质量[卡氏功能状态(KPS)评分]、血清学指标[CC趋化因子配体20(CCL20)、单核细胞趋化因子-1(MCP-1)、血管内皮生长因子(VEGF)]、不良反应发生情况及生存情况。结果观察组患者的总有效率为88.57%,明显高于对照组患者的68.57%,差异有统计学意义(P﹤0.01)。治疗后,两组患者KPS评分均高于本组治疗前,观察组患者KPS评分高于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者血清CCL20、MCP-1、VEGF水平均低于本组治疗前,观察组患者血清CCL20、MCP-1、VEGF水平均低于对照组,差异均有统计学意义(P﹤0.05)。观察组患者的不良反应总发生率为5.71%,低于对照组患者的18.57%,差异有统计学意义(P﹤0.05)。观察组患者的1年生存率为94.29%,高于对照组患者的80.00%,差异有统计学意义(P﹤0.05)。结论FSRT联合全脑放疗治疗乳腺癌脑转移患者可提高近期和远期疗效,改善生活质量,降低血清CCL20、MCP-1、VEGF水平,且安全性较好。 展开更多
关键词 分次立体定向放疗 全脑放疗 乳腺癌 脑转移 临床疗效
下载PDF
Recent advances in breast cancer radiotherapy:Evolution or revolution,or how to decrease cardiac toxicity? 被引量:8
8
作者 Youlia M Kirova 《World Journal of Radiology》 CAS 2010年第3期103-108,共6页
Radiation therapy has a major role in the management of breast cancers.However,there is no consensus on how to irradiate and on volume definitions,and there are strong differences in strategies according to different ... Radiation therapy has a major role in the management of breast cancers.However,there is no consensus on how to irradiate and on volume definitions,and there are strong differences in strategies according to different centers and physicians.New treatment protocols and techniques have been used with the principal purpose of decreasing lung and heart toxicity and adapting radiation treatment to patients' anatomy.There is evidence that indicates internal mammary chain radiotherapy should be used carefully and that high quality techniques should be used for decreasing the dose delivered to the heart.This review of the literature presents the state of the art on breast cancer radiotherapy,with special focus on the indications,techniques,and potential toxicity. 展开更多
关键词 Cardiac toxicity EJECTION fraction Breast cancer radiotherapy Chemotherapy HERCEPTIN
下载PDF
Prospect of radiotherapy technology development in the era of immunotherapy 被引量:2
9
作者 Jian-Yue Jin 《Journal of the National Cancer Center》 2022年第2期106-112,共7页
Radiotherapy(RT)is one of the important modalities for cancer treatments.Mounting evidence suggests that the host immune system is involved in the tumor cell killing during RT,and future RT technology development shou... Radiotherapy(RT)is one of the important modalities for cancer treatments.Mounting evidence suggests that the host immune system is involved in the tumor cell killing during RT,and future RT technology development should aim to minimize radiation dose to the immune system while maintaining a sufficient dose to the tumor.A brief history of RT technology development is first summarized.Three RT technologies,namely FLASH RT,proton therapy,and spatially fractionated RT(SFRT),are singled out for the era of immunotherapy.Besides the technical aspects,the mechanism of FLASH effect is discussed,which is likely the combined results of the recombination effect,oxygen depletion effect and immune sparing effect.The proton therapy should have the advantage of causing much less immune damage in comparison to X-ray based RT due to the Bragg peak.However,the relative biological effectiveness(RBE)uncertainty and range uncertainty may hinder the translation of this advantage into clinical benefit.Research approaches to overcome these two technical hurdles are discussed.Various SFRT approaches and their application are reviewed.These approaches are categorized as single-field 1D/2D SFRT,multi-field 3D SFRT and quasi-3D SFRT techniques.A 3D SFRT approach,which is achieved by placing the Bragg peak of a proton 2D SFRT field in discrete depths,may have special potential because all 3 technologies(FLASH RT,proton therapy and SFRT)may be used in this approach. 展开更多
关键词 radiotherapy technology Immune sparing technique Proton therapy FLASH radiotherapy Spatially fractionated radiotherapy
下载PDF
Observation of the therapeutic efficacy of stereotactic radiotherapy in 44 cases of retroperitoneal metastatic tumor
10
作者 Qingsong Xi Shiying Yu Guangyuan Hu 《The Chinese-German Journal of Clinical Oncology》 CAS 2006年第5期347-349,共3页
Objective: To investigate the therapeutic effects of stereotactic radiotherapy for retroperitoneal metastatic tumor. Methods: From August 1997 to October 2004, 44 patients with retroperitoneal metastatic tumors were t... Objective: To investigate the therapeutic effects of stereotactic radiotherapy for retroperitoneal metastatic tumor. Methods: From August 1997 to October 2004, 44 patients with retroperitoneal metastatic tumors were treated with stereotactic radiotherapy. The planning target volume was encompassed by 90%–95% isodose line. Fractional dose was from 6 Gy to 8 Gy, and they were treated 2–3 times per-week and 4–8 times in all. The total radiation doses of PTV were from 32 Gy to 48 Gy. Re- sults: After the radiotherapy, the pain was obviously relieved in 81.8% patients. Three months after completion of radiotherapy passed and then, abdominal CT was performed to evaluate the results. The whole effective rate was 81.8% [CR 27.7% (12/44) and PR 54.5% (24/44)], and six months after radiotherapy, CR was 27.7% (12/44) and PR was 59.1% (26/44). The middle survival time was 12 months. Conclusion: It is suggested that stereotactic radiotherapy for retroperitoneal metastatic tumor is a safe and effective method. 展开更多
关键词 retroperitoneal metastatic tumor stereotactic radiotherapy fractionated stereotactic radiotherapy
下载PDF
Radiobiological effect of abdominal X-ray hypo-fraction irradiation on Wistar rats liver
11
作者 Peng Qi Yongheng An +1 位作者 Hongsheng Yu Xinjia He 《The Chinese-German Journal of Clinical Oncology》 CAS 2012年第7期395-398,共4页
Objective: The aim of our study was to investigate the impact of abdominal hypo-fraction irradiation on liver damage in rats so as to provide a reference for its clinical application. Methods: A total of 100 Wistar ra... Objective: The aim of our study was to investigate the impact of abdominal hypo-fraction irradiation on liver damage in rats so as to provide a reference for its clinical application. Methods: A total of 100 Wistar rats were equally randomized to five groups as control, 4 Gy, 6 Gy, 8 Gy and 12 Gy group, and the corresponding fractionated doses were offered. Liver functions were examined at the 2nd, 4th, 6th, 8th and 10th week after irradiation. Morphological changes were observed by HE staining. Expressions of Bcl-2 and Bax were examined by immunohistochemical technique. Results: In all irradiation groups, hepatocellular swell, degeneration, necrosis and even hepatic fibrosis could be seen. The differences of the liver coefficient, Glutamyl pyruvic transaminase (GPT), Glutamyl oxaloacetic transaminase (GOT) were significant among the groups and different time points (F = 11.833-781.972, F = 20.857-264.692, P < 0.001). Expressions of Bcl-2 and Bax were significantly different between each group (F = 211.607, 116.577; P < 0. 001), and between each time point (F = 54.083, 68.749; P < 0. 001). Conclusion: Compare with conventional fraction, abdominal hypo-fraction irradiation may cause radiation damage to rat liver, being dose-and-time dependent. Up-regulation of activating apoptosis protein Bax and down-regulation of inhibiting apoptosis protein Bcl-2 may involve in the process. 展开更多
关键词 radiotherapy dose fractionation LIVER radiobiological effects apoptosis BCL-2/BAX
下载PDF
Efficacy of Daily Cone-Beam Computed Tomography as Part of a Rescan Protocol for Large Offset to Reduce the Inter-Fractional Motion of the Prostate
12
作者 Shinsaku Yamaguchi Takayuki Ohguri +7 位作者 Hajime Imada Katsuya Yahara Hiroyuki Narisada Satoshi Iwasaki Toshihiro Onoda Yuta Ezaki Eiji Hamada Yukunori Korogi 《International Journal of Medical Physics, Clinical Engineering and Radiation Oncology》 2014年第4期193-200,共8页
Purpose: To prospectively analyze the inter-fractional motion of the prostate in patients with prostate cancer treated with intensity-modulated radiation therapy (IMRT) using image-guided radiotherapy (IGRT) with dail... Purpose: To prospectively analyze the inter-fractional motion of the prostate in patients with prostate cancer treated with intensity-modulated radiation therapy (IMRT) using image-guided radiotherapy (IGRT) with daily cone-beam computed tomography (CBCT) as part of a rescan protocol for large offset, and to evaluate the efficacy of our protocol. Materials and Methods: Eligible patients were treated with the following protocol: 1) magnesium oxide and dimethylpolysiloxane were administered to ensure that patients had regular bowel movements;2) the patients were instructed to have an appropriately distended bladder during the planning CT and daily irradiation;3) the daily CBCT image was fused with the planning CT image using the prostate outline;and 4) if large offset was recognized, a rescan CBCT image was obtained after appropriate countermeasures, such as the discharge of gas and defecation, and re-registration was performed. Three shifts for the inter-fractional motion of the prostate were analyzed, in the fractions which needed the CBCT rescan;the displacement data after the final rescan were used. Results: Sixty-one patients were eligible, and a total of 2302 fractions were available for the analysis. Rescans of the CBCT for large offset were performed in 113 (5%) of the 2302 fractions. After the first rescan, the large offset was resolved in 106 (94%) of the 113 fractions. Excessive rectal gas was the reason for the large offset in 94 (83%) of the 113 fractions. The total mean and standard deviation of the inter-fractional motion of the prostate in the AP, LR, and SI directions were 1.1 ± 2.4, -0.1 ± 2.3, and 0.7 ± 3.0 mm, respectively. Conclusion: Large offset was recognized in 5% of all fractions. Daily CBCT with our rescan protocol could resolve the large offset, which was mainly caused by excessive rectal gas, and it may therefore be promising to reduce the inter-fractional motion of the prostate. 展开更多
关键词 INTENSITY-MODULATED radiotherapy PROSTATE Cancer DAILY Cone Beam Computed Tomography Inter-fractional MOTION
下载PDF
早期乳腺癌保乳术后瘤床不同补量放疗模式的疗效及安全性
13
作者 张梦 柔倩 +2 位作者 刘莹 孜那提·努尔太 成芳 《癌症进展》 2023年第12期1323-1326,1352,共5页
目的 比较早期乳腺癌保乳术后全乳大分割放疗序贯瘤床大分割补量与瘤床常规分割补量的疗效及安全性。方法 按照瘤床补量放疗模式的不同将120例早期乳腺癌保乳术后全乳大分割放疗患者分为瘤床大分割组(n=30,序贯瘤床大分割补量870 cGy/3... 目的 比较早期乳腺癌保乳术后全乳大分割放疗序贯瘤床大分割补量与瘤床常规分割补量的疗效及安全性。方法 按照瘤床补量放疗模式的不同将120例早期乳腺癌保乳术后全乳大分割放疗患者分为瘤床大分割组(n=30,序贯瘤床大分割补量870 cGy/3 f)和瘤床常规分割组(n=90,序贯瘤床常规分割补量1000 cGy/5 f)。比较两组患者的乳房美容效果、不良反应发生率、住院时间及预后。结果 放疗后1、6个月,两组患者的乳房美容效果优良率比较,差异均无统计学意义(P>0.05)。两组患者骨髓抑制、急性皮肤不良反应、晚期皮肤不良反应、放射性肺炎发生率比较,差异均无统计学意义(P>0.05)。两组患者的住院时间比较,差异无统计学意义(P>0.05)。两组患者的2年局部控制率和生存率均为100%。结论 早期乳腺癌保乳术后全乳大分割放疗已成为目前放疗的主流模式,序贯瘤床大分割补量与序贯瘤床常规分割补量的乳房美容效果和不良反应均无明显差异,患者的2年局部控制率及生存率均较高。在瘤床区域有钛夹标记的前提下,可优先选择更精准的三维适形调强放疗技术进行大分割瘤床补量放疗。 展开更多
关键词 早期乳腺癌 保乳术 大分割放疗 常规分割放疗 瘤床标记 疗效
下载PDF
低剂量分次放疗增敏化疗治疗晚期结直肠癌的临床效果
14
作者 熊春 黄丹 马智 《中外医药研究》 2023年第12期57-59,共3页
目的:探讨对晚期结直肠癌患者采取低剂量分次放疗增敏化疗(LDFRT)治疗的有效性及可行性。方法:选取2017年3月—2019年3月广西科技大学第一附属医院肿瘤科经病理学或组织学确诊的40例晚期结直肠癌患者为研究对象,按照随机数字表法分为对... 目的:探讨对晚期结直肠癌患者采取低剂量分次放疗增敏化疗(LDFRT)治疗的有效性及可行性。方法:选取2017年3月—2019年3月广西科技大学第一附属医院肿瘤科经病理学或组织学确诊的40例晚期结直肠癌患者为研究对象,按照随机数字表法分为对照组和试验组,各20例。对照组给予常规化疗治疗,试验组在对照组基础上联合LDFRT治疗。比较两组近期疗效、不良反应、总生存期(OS)和无进展生存期(PFS)、免疫功能。结果:试验组客观缓解率高于对照组,差异有统计学意义(P=0.038);试验组中位OS、PFS长于对照组,差异有统计学意义(P<0.05);试验组、对照组不良反应发生率比较,差异无统计学意义(P>0.05);治疗后,试验组CD8+低于对照组,CD4+、CD4+/CD8+、中性粒细胞计数、淋巴细胞计数水平均高于对照组,差异有统计学意义(P<0.05)。结论:LDFRT治疗晚期结直肠癌患者效果较好,能延长患者无进展生存时间,增加患者免疫功能,不会增加不良反应。 展开更多
关键词 低剂量分次放疗增敏化疗 晚期结直肠癌 免疫功能
下载PDF
不同分割模式调强放疗NSCLC脑部寡转移的疗效及放射性脑损伤发生情况分析
15
作者 庞然然 《实用癌症杂志》 2023年第2期266-269,共4页
目的研究不同分割模式调强放疗对NSCLC脑部寡转移的疗效及放射性脑损伤发生情况及预后分析。方法选取收治的82例非小细胞肺癌(NSCLC)脑部寡转移患者作为研究对象,根据患者的分割模式分为大分割组(n=38)和对照组(n=44)。对比两组患者放... 目的研究不同分割模式调强放疗对NSCLC脑部寡转移的疗效及放射性脑损伤发生情况及预后分析。方法选取收治的82例非小细胞肺癌(NSCLC)脑部寡转移患者作为研究对象,根据患者的分割模式分为大分割组(n=38)和对照组(n=44)。对比两组患者放疗后的临床疗效以及放射性脑损伤发生率;对比两组患者治疗期间不良反应发生率和1年生存率。结果相比于对照组临床有效率[65.91%(29/44)],大分割组[78.95%(30/38)]显著更高(P<0.05);大分割组患者放射性脑损伤发生率[7.89%(3/38)]与对照组[4.55%(2/44)]相比,差异无统计学意义(P>0.05);大分割组患者不良反应发生率[10.53%(4/38)]与对照组[11.36%(5/44)]相比,差异无统计学意义(P>0.05);大分割组患者1年内生存率[63.16%(24/38)]与对照组患者[59.09%(26/44)]相比,差异无统计学意义(P>0.05)。结论与常规分割模式调强放疗相比,大分割模式调强放疗治疗NSCLC脑部寡转移疗效更高,但放射性脑损伤、不良反应发生率以及1年内生存率并不具有差异性。 展开更多
关键词 分割模式 放疗 NSCLC 脑部寡转移 放射性脑损伤
下载PDF
分次立体定向放疗同步化疗联合贝伐珠单抗治疗肺癌脑转移的疗效及安全性 被引量:6
16
作者 梁丹 张又红 +3 位作者 苏天海 冯波 杨相辉 王桂华 《中南药学》 CAS 2023年第3期823-827,共5页
目的探讨分次立体定向放疗同步化疗联合贝伐珠单抗治疗非小细胞肺癌脑转移患者的疗效及安全性。方法选取45例非小细胞肺癌脑转移的患者进行回顾性研究,根据治疗方法的不同分为观察组(n=22)和对照组(n=23)。两组均采用分次立体定向放疗... 目的探讨分次立体定向放疗同步化疗联合贝伐珠单抗治疗非小细胞肺癌脑转移患者的疗效及安全性。方法选取45例非小细胞肺癌脑转移的患者进行回顾性研究,根据治疗方法的不同分为观察组(n=22)和对照组(n=23)。两组均采用分次立体定向放疗同步化疗,观察组在此基础上联合贝伐珠单抗。比较两组的客观缓解率(ORR)、疾病控制有效率(DCR)、颅内高压缓解率、卡氏评分(KPS)改善情况、1年复发率和颅内疾病无进展生存时间(iPFS),记录两组的不良反应。结果观察组的ORR为59.09%,高于对照组的26.09%(P<0.05);两组的DCR分别为86.36%和69.57%(P>0.05)。观察组的颅内高压缓解率为59.09%,高于对照组的21.74%(P<0.05)。观察组的KPS评分上升率为68.18%,较对照组的39.13%有改善趋势(P=0.05)。观察组的1年复发率为40.91%,低于对照组的73.91%(P<0.05);观察组的iPFS为17.22个月,长于对照组的10.30个月(P<0.05)。两组不良反应相近(P>0.05)。结论在非小细胞肺癌脑转移患者中,分次立体定向放疗同步化疗联合贝伐珠单抗能提高ORR,改善颅内高压症状和生存质量,降低1年复发率和延长颅内无疾病进展时间,具有肯定的临床疗效和良好的安全性。 展开更多
关键词 非小细胞肺癌 脑转移 分次立体定向放疗 化疗 贝伐珠单抗
下载PDF
局部晚期高危乳腺癌根治术后辅助低分割放疗的临床应用
17
作者 沈琳 陈方 +1 位作者 马伶玉 陈理明 《深圳中西医结合杂志》 2023年第5期1-6,F0003,共7页
目的:探索在局部晚期高危乳腺癌根治术后辅助放疗采用不同放疗分割方式对无进展生存期(PFS)的影响。方法:回顾性分析香港大学深圳医院2015年6月至2021年5月腋窝淋巴结阳性N3期、接受过乳房根治性切除术且接受术后辅助放疗的局部晚期高... 目的:探索在局部晚期高危乳腺癌根治术后辅助放疗采用不同放疗分割方式对无进展生存期(PFS)的影响。方法:回顾性分析香港大学深圳医院2015年6月至2021年5月腋窝淋巴结阳性N3期、接受过乳房根治性切除术且接受术后辅助放疗的局部晚期高危乳腺癌患者的资料,患者的放疗分割方式采用低分割放疗及常规分割放疗,分析两种放疗方式对患者PFS的影响,用Kaplan-Meier法绘制患者生存曲线,并比较PFS差异;单因素和多因素Cox风险比例模型研究两种不同放疗分割方式对PFS的影响。结果:共纳入患者134例,患者中位年龄45岁,其中接受低分割放疗95例,接受常规分割放疗39例。中位随访时间为52个月,Cox回归分析显示:T分期是PFS的影响因素(P<0.05),放疗分割方式并非PFS的影响因素(P=0.160),矫正混杂因素T分期后,放疗分割方式亦非PFS的影响因素(P=0.069)。结论:局部晚期浸润性乳腺癌根治术后辅助放疗在本中心单一机构的临床实践中,低分割放疗与常规分割放疗疗效相似,患者PFS差异无统计学意义。低分割放疗能明显缩短患者的治疗周期,实现在有限的时间和设备资源条件下,为更多的患者提供服务。 展开更多
关键词 乳腺癌 乳腺癌根治术 低分割放疗 常规分割放疗 调强放疗
下载PDF
边界距离散射剂量计划模式对肺癌脑转移瘤射波刀治疗的剂量学影响研究
18
作者 朱向辉 王震岳 +2 位作者 张效亮 高行新 田种泽 《医疗卫生装备》 CAS 2023年第12期42-45,共4页
目的:探讨边界距离散射剂量(boundary range scattering dose,BRSD)计划模式对肺癌脑转移瘤射波刀治疗的剂量学影响。方法:选取2021年1月1日至2021年12月31日在某院放射治疗科治疗的15例肺癌脑转移瘤患者的定位影像资料,将其导入射波刀... 目的:探讨边界距离散射剂量(boundary range scattering dose,BRSD)计划模式对肺癌脑转移瘤射波刀治疗的剂量学影响。方法:选取2021年1月1日至2021年12月31日在某院放射治疗科治疗的15例肺癌脑转移瘤患者的定位影像资料,将其导入射波刀的Multiplan 4.0.3治疗计划系统,针对每名患者分别制订分次立体定向放疗(fractio-nated stereotactic radiotherapy,FSRT)计划(作为FSRT计划组)和BRSD计划(作为BRSD计划组)。其中FSRT计划组按常规方法针对计划靶区(planning target volume,PTV)制订计划,使V_(100)覆盖95%以上的PTV;BRSD计划组针对大体肿瘤靶区(gross tumor volume,GTV)制订计划,参数条件与FSRT计划组相同,并最终归一处方剂量到PTV上,使V_(100)覆盖95%以上的PTV。通过剂量体积直方图和等剂量曲线分布图比较2组靶区和正常组织的剂量学参数。采用SPSS 24.0软件进行统计学分析。结果:BRSD计划组靶区的D_(98)、D_(max)、D_(mean)明显高于FSRT计划组,差异有统计学意义(P<0.05);2组的适形性指数、剂量梯度指数及正常组织的D_(mean)、V_(30)、V_(24)、D_(3 cc)比较,差异均无统计学意义(P>0.05);BRSD计划组的靶区内剂量分布更为密集。结论:BRSD计划模式在不增加或降低正常组织剂量的情况下,能够显著提升靶区吸收剂量,具有明显的剂量学优势。 展开更多
关键词 射波刀 肺癌脑转移瘤 FSRT BRSD
下载PDF
中晚期非小细胞肺癌中常规分割放疗与超分割放疗的临床研究
19
作者 梁淑芳 赵弟庆 马勇 《中外医疗》 2023年第35期29-32,共4页
目的探究常规分割放疗(radiotherapy,RT)与加速超分割放疗(accelerated hyperfractionated radiotherapy,AHRT)在治疗中晚期非小细胞肺癌的疗效和不良反应。方法回顾性分析2021年1月—2022年6月菏泽市牡丹人民医院不能手术或拒绝手术的6... 目的探究常规分割放疗(radiotherapy,RT)与加速超分割放疗(accelerated hyperfractionated radiotherapy,AHRT)在治疗中晚期非小细胞肺癌的疗效和不良反应。方法回顾性分析2021年1月—2022年6月菏泽市牡丹人民医院不能手术或拒绝手术的60例中晚期非小细胞肺癌患者的临床资料。根据治疗方式的不同分为对照组30例,观察组30例,对照组采用常规分割方式治疗,观察组采用加速超分割方式治疗。比较两组疗效、生存率、不良反应发生情况。结果观察组近期有效率为93.33%,高于对照组的73.33%,差异有统计学意义(χ^(2)=10.961,P<0.05)。两组不良反应发生情况比较,差异无统计学意义(P>0.05)。结论加速超分割放疗优于常规分割放疗,且不会增加放疗不良反应发生率。 展开更多
关键词 常规分割放疗 加速超分割放疗 中晚期 非小细胞肺癌
下载PDF
Comparison of linac-based fractionated stereotactic radiotherapy and tomotherapy treatment plans for intra-cranial tumors
20
作者 Jang Bo Shim Suk Lee +12 位作者 Sam Ju Cho Sang Hoon Lee Juree Kim Kwang Hwan Cho Chul Kee Min Hyun Do Huh Rena Lee Dae Sik Yang Young Je Park Won Seob Yoon Chul Yong Kim Soo Il Kwon 《Chinese Physics C》 SCIE CAS CSCD 2010年第11期1768-1774,共7页
This study compares and analyzes stereotactic radiotherapy using tomotherapy and linac-based fractionated stereotactic radiotherapy in the treatment of intra-cranial tumors,according to some cases.In this study,linac-... This study compares and analyzes stereotactic radiotherapy using tomotherapy and linac-based fractionated stereotactic radiotherapy in the treatment of intra-cranial tumors,according to some cases.In this study,linac-based fractionated stereotactic radiotherapy and tomotherapy treatment were administered to five patients diagnosed with intra-cranial cancer in which the dose of 18–20 Gy was applied on 3–5 separate occasions.The tumor dosing was decided by evaluating the inhomogeneous index (II) and conformity index (CI).Also,the radiation-sensitive tissue was evaluated using low dose factors V1,V2,V3,V4,V5,and V10,as well as the non-irradiation ratio volume (NIV).The values of the II for each prescription dose in the linacbased non-coplanar radiotherapy plan and tomotherapy treatment plan were (0.125±0.113) and (0.090±0.180),respectively,and the values of the CI were (0.899±0.149) and (0.917±0.114),respectively.The low dose areas,V1,V2,V3,V4,V5,and V10,in radiation-sensitive tissues in the linac-based non-coplanar radiotherapy plan fell into the ranges 0.3%–95.6%,0.1%–87.6%,0.1%–78.8%,38.8%–69.9%,26.6%–65.2%,and 4.2%–39.7%,respectively,and the tomotherapy treatment plan had ranges of 13.6%–100%,3.5%–100%,0.4%–94.9%,0.2%– 82.2%,0.1%–78.5%,and 0.3%–46.3%,respectively.Regarding the NIV for each organ,it is possible to obtain similar values except for the irradiation area of the brain stem.The percentages of NIV10%,NIV20%,and NIV30%for the brain stem in each patient were 15%–99.8%,33.4%–100%,and 39.8%–100%,respectively,in the fractionated stereotactic treatment plan and 44.2%–96.5%,77.7%–99.8%,and 87.8%–100%,respectively,in the tomotherapy treatment plan.In order to achieve higher-quality treatment of intra-cranial tumors,treatment plans should be tailored according to the isodose target volume,inhomogeneous index,conformity index,position of the tumor upon fractionated stereotactic radiosurgery,and radiation dosage for radiation-sensitive tissues. 展开更多
关键词 fractionated stereotactic radiotherapy TOMOTHERAPY treatment plan virtual organ delineation
原文传递
上一页 1 2 16 下一页 到第
使用帮助 返回顶部